Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CHAPEL HILL, N.C., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Bamboo Therapeutics, a biotechnology company focused on developing gene therapies for rare neurological diseases, announced today that it had acquired the viral gene therapy manufacturing facility (“Vector Core”) from the University of North Carolina (UNC) at Chapel Hill, N.C. Financial Details are not disclosed.
The Vector Core was founded in 1993 as a full-service viral vector production organization with extensive experience in vector design and process development, as well as manufacturing of research and clinical grade vectors. This 11,000 square foot facility has produced multiple research grade and clinical grade lots for pharmaceutical and biotechnology companies, as well as universities and foundations.
Bamboo has developed a proprietary suspension cell-based production platform that utilizes serum free/chemically defined media to increase scalability, efficiency and purity. Our proprietary system decreases the amount of processing steps necessary in methods using adherent cells, while also reducing the variability and shortcomings associated with using animal serum, giving Bamboo superior vector yields at a lower cost.
“We believe that having a leading manufacturing facility fully integrated into our business provides flexibility and a competitive advantage,” stated Dr. Jude Samulski, Scientific Founder and Chairman of Bamboo Therapeutics. “We anticipate rapidly moving our programs forward, including our DMD program, which is expected to enter the clinic in early 2017.”
About Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. is a fully integrated, clinical stage gene therapy company developing therapeutics to treat central nervous system and neuromuscular diseases. Bamboo combines its own in-house expertise in AAV gene therapy research, vector manufacturing, clinical development, and regulation of gene therapy products with collaborations with academic experts in rare neurologic disease areas of mutual interest. The company’s pipeline is focused on diseases of high unmet need, including giant axonal neuropathy (GAN), Canavan disease, Friedreich’s ataxia and Duchenne muscular dystrophy. Bamboo’s most advanced programs is for GAN, which is currently in a phase 1/2 trial.
Contact Richard E. T. Smith, PhD SVP, Corporate Communications and External Affairs [email protected]
